TICKERNERD
Menu
AIFFAIFFTechnology · Software - Application

AIFF Stock Forecast: Firefly Neuroscience, Inc. Price Predictions for 2026-2027

Last close, 14 Oct 2026
$1.07
−3.60% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 39 of 100 as at 14 Oct 2026 — in the lower half.

Market cap
$17.6M
Ticker Nerd rank
39 / 100
Median analyst target
—
Analysts covering
0
Revenue$514K+71.9% y/y
Operating income−$2.0M
Net income−$2.0M
Free cash flow−$1.8M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−12.3%
1M
+1.9%
YTD
+21.6%
1Y
−61.1%
From 52W high
−64.6%
From 52W low
+67.2%
$0.64
$3.02
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

AIFF stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Firefly Neuroscience, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 14 Oct 2026
39 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Growth
100
Size
88
Accruals
72
Momentum
38
Volatility
37
Issuance
31
Quality
31
Revisions
25
Value
13

Growth (100): Sales and profits are climbing, and climbing faster than before.

Value (13): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

AIFF stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on AIFF, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$0.50$1.00$1.50$2.00$2.50$3.00Jan 26Apr 26Jul 26Oct 26AIFF

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. AIFF appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

AIFF vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 14 Oct 2026, Firefly Neuroscience, Inc. returned −61.1% against +17.5% for the S&P 500, dividends included.

AIFF vs S&P 500, last 12 monthsTotal return, rebased to 100
20406080100120Jan 26Apr 26Jul 26Oct 26AIFFS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

AIFF analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Fundamentals

Firefly Neuroscience, Inc. (AIFF) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−0.6×

Cheaper than 81% of US stocks

Price / sales
9.8×

Cheaper than 14% of US stocks

Price / book
1.2×

Cheaper than 64% of US stocks

EV / EBITDA
−1.0×

Cheaper than 68% of US stocks

Growth & margins
Revenue growth (YoY)
71.9%

Higher than 90% of US stocks

Earnings growth (YoY)
71.9%

Higher than 80% of US stocks

Gross margin
49.2%

Higher than 61% of US stocks

Operating margin
−384.0%

Higher than 8% of US stocks

Net margin
56.5%

Higher than 97% of US stocks

Returns & dividend
Return on equity
−68.1%

Higher than 18% of US stocks

Return on assets
−34.9%

Higher than 12% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Firefly Neuroscience, Inc. (AIFF) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Firefly Neuroscience, Inc. has a market value of $17.6M and an enterprise value of $8.3M.

  • Revenue in the twelve months to 30 June 2026: $1.8M. The latest quarter grew 71.9% year on year.

  • Net income over the same four quarters: −$9.1M, a −506.2% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$7.2M.

  • Shares outstanding: 15.6M.

  • Trailing P/E: −0.6×.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Firefly Neuroscience, Inc. employs 17 people — $106K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Oct 2026

Data provided by Twelve Data

Peers

AIFF vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelSoftware - Application
CompanyMarket capTKN rank
AIFFFirefly Neuroscience, Inc.$17.6M
39
VIDAVida Global, Inc.$16.3M
2
RPGLRepublic Power Group Ltd.$16.2M
2
IPMIntelligent Protection Management Corp.$15.9M
45
YAASYouxin Technology Ltd.$15.7M
19
IDAIT Stamp, Inc.$15.6M
24
MNDOMIND C.T.I. Ltd.$18.7M
85

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Firefly Neuroscience, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest AIFF news & analysis

Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care

Benzinga · 25 Sept 2026positive

Firefly Neuroscience Inc. (NASDAQ:AIFF) announced a partnership with bioelectronic medical device firm NeuroSigma, Inc. The collaboration aims to expand clinician awareness and access to the Monarch eTNS System across the U.S., broadening non-drug pediatric ADHD care options.

Why it matters — This partnership expands the market reach of a non-pharmaceutical pediatric ADHD treatment, potentially growing Firefly's commercial footprint in the precision neuroscience space.

Firefly (NASDAQ: AIFF) and NeuroSigma Partner to Expand Access to First FDA-Cleared, Non-Drug Treatment for Pediatric ADHD

GlobeNewsWire · 25 Sept 2026positive

Firefly Neuroscience announced a partnership with NeuroSigma to bring NeuroSigma's second-generation Monarch eTNS System to Firefly's nationwide network of Evoke clinicians. The collaboration aims to expand access to the first FDA-cleared, non-drug treatment for pediatric ADHD.

Why it matters — The partnership could broaden Firefly's clinical reach and add a notable FDA-cleared treatment option to its Evoke clinician network.

Firefly Neuroscience's Evoke™ Platform Selected to Bring Objective Brain-Function Insights to Radial's AI-Native Operating System for Brain Medicine

GlobeNewsWire · 17 Sept 2026positive

Firefly Neuroscience's Evoke™ Platform has been selected by Radial to provide objective brain-function insights for Radial's AI-native operating system for brain medicine. The integration will use Firefly's FDA 510(k)-cleared, AI-powered EEG/ERP technology.

Why it matters — This selection expands Firefly's cleared EEG/ERP technology into Radial's large brain medicine clinical network, broadening its commercial reach.

Firefly Neuroscience (NASDAQ: AIFF) and Next Health Launch Precision Cognitive Health Initiative as FDA Advisory Committee's Recommendation Backs Broader Access to Key Neuroprotective Peptides

GlobeNewsWire · 28 July 2026positive

Firefly Neuroscience (AIFF) and Next Health launched a Precision Cognitive Health Initiative. Separately, an FDA Advisory Committee voted to recommend easing compounding restrictions for six peptides, including Epitalon and Semax.

Why it matters — For AIFF watchers, the launch of the cognitive health initiative could expand the company's commercial reach, while the FDA committee's recommendation may open broader access to neuroprotective peptides relevant to AIFF's focus.

FAQ

Frequently asked questions about AIFF stock

How does Ticker Nerd's model rank AIFF?

As at 14 Oct 2026, Firefly Neuroscience, Inc. ranks 39 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Growth (100 of 100).

What is the AIFF stock forecast for 2030?

No analyst covering Firefly Neuroscience, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for AIFF are extrapolating price history, which says nothing about the business.

How has AIFF stock performed over the past year?

Firefly Neuroscience, Inc. returned -61.1% over the 12 months to 14 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Firefly Neuroscience, Inc. do?

Firefly Neuroscience Inc. is a medical technology and artificial intelligence company focused on neuroscientific solutions for mental illnesses and neurological disorders.

What is the latest news on AIFF?

The most recent item we track (Benzinga, 25 Sept 2026): "Firefly Neuroscience and Neurosigma Partner To Expand Non-Drug Pediatric ADHD Care". Firefly Neuroscience Inc. (NASDAQ:AIFF) announced a partnership with bioelectronic medical device firm NeuroSigma, Inc. The collaboration aims to expand clinician awareness and access to the Monarch eTNS System across the U.S., broadening non-drug pediatric ADHD care options.

Company

About Firefly Neuroscience, Inc.

Firefly Neuroscience Inc. is a medical technology and artificial intelligence company focused on neuroscientific solutions for mental illnesses and neurological disorders. Its core product is the FDA-cleared Brain Network Analytics platform, which analyzes EEG and ERP data to help clinicians evaluate brain function and support diagnostic and treatment decisions. The company’s offerings are designed for use in settings addressing conditions such as depression, dementia, anxiety disorders, concussions, ADHD, and other cognitive or neurological disorders. Firefly Neuroscience also provides the Evoke System, a brain assessment tool that generates structured reports from neurophysiological data. The company serves clinicians and other healthcare professionals across North America, positioning itself within the growing field of digital brain health and precision neuroscience.

CEO Mr. Greg Lipschitz · 17 employees · United States · https://fireflyneuro.com